Randomized Phase 2 Trial of Sacituzumab Govitecan With or Without Pembrolizumab in First-line Metastatic PD-L1-negative TNBC

Sponsor:

Dana-Farber Cancer Institute - DFCI

Sponsor Study ID:

20-166

CTO #:

104165

NCT Number:

NCT04468061

Phase:

II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Breast

Study Objectives:

To compare the progression free survival of sacituzumab govitecan with pembrolizumab to that of sacituzumab govitecan alone in patients with PD-L1 negative metastatic TNBC, who have not recieved prior thereapy for metastatic breast cancer and who have not recieved a prior PD-1/L1 inhibitor.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)